Celgene/Agios Team Up In Long-Term Cancer Metabolism Pact
This article was originally published in The Pink Sheet Daily
Executive SummaryAgios will receive $130 million upfront, while Celgene gains the option to develop any drugs resulting from the biotech's cancer metabolism research platform for an undisclosed period of time.
You may also be interested in...
Abbott sends another financial record tumbling as it pays an all-time high $400 million upfront for preclinical AIM compounds from Reata.